SAB Biotherapeutics
SAB Biotherapeutics is developing SAB-142, a fully-human antibody aimed at delaying the onset and progression of Type 1 Diabetes by targeting the over-reactive immune response that attacks insulin-producing beta cells.
SAB Biotherapeutics Services
SAB Biotherapeutics specializes in developing fully human immunotherapies to treat and prevent immune and autoimmune disorders. Their key service involves leveraging transgenic cows to sustainably and scalably produce fully human antibodies, eliminating the dependence on human donors. Their capabilities extend to producing disease-modifying therapies, with a focus on Type 1 Diabetes (T1D) and influenza.
SAB Biotherapeutics Products
SAB Biotherapeutics' lead product is SAB-142, a fully human IgG antibody designed to delay the onset and progression of Type 1 Diabetes (T1D). It targets the over-reactive immune response that damages insulin-producing beta cells in the pancreas. The company has also developed SAB-176, which has received Fast Track and Breakthrough Therapy Designations from the FDA for targeting multiple strains of influenza. Overall, the company focuses on creating high-potency immunoglobulins using their DiversitAb platform.
SAB Biotherapeutics Research and Development
SAB Biotherapeutics' Research & Development Campus is located in Sioux Falls, SD. The company has conducted seven clinical trials (Phase 1, 2, and 3) with over 700 individuals dosed with their proprietary hIgGs. Their R&D efforts include preparing regulatory submissions (CTA/CTN/IND) for the Type 1 diabetes indication for SAB-142. The company is committed to advancing their pipeline and utilizing their unique platform to address immune and autoimmune diseases.
SAB Biotherapeutics Headquarters
SAB Biotherapeutics is headquartered in Miami Beach, FL. In addition to their main office, they operate a Research & Development Campus in Sioux Falls, SD. From these locations, they manage their clinical trials, development projects, and overall business operations, focused on delivering fully human immunotherapies to the market.